2026 Q2 -tulosraportti
50 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 47 | - | - | ||
| 215 | - | - | ||
| 205 | - | - | ||
| 1 570 | - | - | ||
| 1 186 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenScenario where 48.22 is the top after a rise from 23.52. Note! Not a forecast or investment advice. A normal larger pullback could land somewhere around 38–36, while a really strong retracement could take it towards 33. Below 38.78 on a clear close, the picture starts to deteriorate. Then I look towards: 35.88 then 32.96 thereafter 29.18 The 50 %-level at 35.88 is particularly important. If the price falls there and then fails to regain 38–39, it starts to look more like the rise from 23.52 is actually finished." And if 32.96 is also broken with clear price structure, then it is a very deep retracement and the risk increases sharply for a test of 29.18. The negative scenario is: 48.22 top → 42.40 broken → 40.74 broken → 38.78 broken Then I would no longer consider the decline as a normal small pullback. Then 35.88 is my first larger target and thereafter 32.96. Below 32.96, 29.18 becomes interesting. Bullish would be: 48.22 → pullback to 42–43 → higher low → above 48.22 48.22 breakout with volume → 54.0–54.9 → 57.6 → 60.5 → 63.5 My opinion and not advice.
Well, how unexpected that you pop up like a jack-in-the-box 😂. How sad to always have such a negative and unrealistic view on everything, almost tragic…
·3.9.Regarding gene therapy - Ongoing projects in addition to Renée's information about broadening the gene therapy business Généthon (Crigler-Najjar syndrome): The clinical phase 2 study (GNT-018-IDES) evaluates imlifidase as pre-treatment before gene therapy GNT-0003. The next major milestone is expected in the second half of 2026, when patient recruitment for the study is estimated to be fully completed. This will be followed by data analysis before moving on to registration-enabling studies. Sarepta Therapeutics (Duchenne muscular dystrophy): The initial clinical phase 1 study (where patients with antibodies were successfully pre-treated with imlifidase before receiving gene therapy) has been completed. Strategic discussions are currently underway regarding the next steps and the design of future clinical studies to advance the combination treatment towards the market. (Hansa’s financial participation Potential total deal value for Hansa amounts toup to USD ~400m plus royalties and incremental imlifidase sales - excerpt from presentation see link below ) AskBio (Pompe disease): This collaboration is at an earlier stage where the companies are evaluating the possibility of using imlifidase to enable gene therapy for Pompe disease. The collaboration with AskBio (entered into in 2022) represents a clear broadening of Hansa's indication area within gene therapy. By entering Pompe disease, Hansa showed that their enzyme platform (imlifidase) is not only limited to muscle diseases (like the collaboration with Sarepta in Duchenne muscular dystrophy), but can be applied to entirely new indications. Here below you can read, there is guaranteed more current information, but still interesting : https://www.hansabiopharma.com/files/Presentations/2021/20211104-HNSA-HCA-event-Gene-Therapy-FINAL.pdf
That thing with AskBio seems really interesting. If they choose to proceed to a full development and commercialization license, Hansa will get a new structure with milestones and royalties. The Sarepta agreement also shows what economic potential such a setup can have. At the same time, we have Généthon in phase 2, and now Renée says they want to further broaden the gene therapy side. A lot is starting to happen there.- ·2.9.My opinion and not advice 👇
- ·2.9.Surely the gene therapy deal will be reached before December!?Hi StigB! It's absolutely possible. The CEO is now saying that they actively want to expand the gene therapy area through new partnership agreements. With existing collaborations with Sarepta and Genethon, I think the chances are good for December.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 468 060 | 468 060 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 468 060 | 468 060 | 0 | 0 |
2026 Q2 -tulosraportti
50 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenScenario where 48.22 is the top after a rise from 23.52. Note! Not a forecast or investment advice. A normal larger pullback could land somewhere around 38–36, while a really strong retracement could take it towards 33. Below 38.78 on a clear close, the picture starts to deteriorate. Then I look towards: 35.88 then 32.96 thereafter 29.18 The 50 %-level at 35.88 is particularly important. If the price falls there and then fails to regain 38–39, it starts to look more like the rise from 23.52 is actually finished." And if 32.96 is also broken with clear price structure, then it is a very deep retracement and the risk increases sharply for a test of 29.18. The negative scenario is: 48.22 top → 42.40 broken → 40.74 broken → 38.78 broken Then I would no longer consider the decline as a normal small pullback. Then 35.88 is my first larger target and thereafter 32.96. Below 32.96, 29.18 becomes interesting. Bullish would be: 48.22 → pullback to 42–43 → higher low → above 48.22 48.22 breakout with volume → 54.0–54.9 → 57.6 → 60.5 → 63.5 My opinion and not advice.Well, how unexpected that you pop up like a jack-in-the-box 😂. How sad to always have such a negative and unrealistic view on everything, almost tragic…
- ·3.9.Regarding gene therapy - Ongoing projects in addition to Renée's information about broadening the gene therapy business Généthon (Crigler-Najjar syndrome): The clinical phase 2 study (GNT-018-IDES) evaluates imlifidase as pre-treatment before gene therapy GNT-0003. The next major milestone is expected in the second half of 2026, when patient recruitment for the study is estimated to be fully completed. This will be followed by data analysis before moving on to registration-enabling studies. Sarepta Therapeutics (Duchenne muscular dystrophy): The initial clinical phase 1 study (where patients with antibodies were successfully pre-treated with imlifidase before receiving gene therapy) has been completed. Strategic discussions are currently underway regarding the next steps and the design of future clinical studies to advance the combination treatment towards the market. (Hansa’s financial participation Potential total deal value for Hansa amounts toup to USD ~400m plus royalties and incremental imlifidase sales - excerpt from presentation see link below ) AskBio (Pompe disease): This collaboration is at an earlier stage where the companies are evaluating the possibility of using imlifidase to enable gene therapy for Pompe disease. The collaboration with AskBio (entered into in 2022) represents a clear broadening of Hansa's indication area within gene therapy. By entering Pompe disease, Hansa showed that their enzyme platform (imlifidase) is not only limited to muscle diseases (like the collaboration with Sarepta in Duchenne muscular dystrophy), but can be applied to entirely new indications. Here below you can read, there is guaranteed more current information, but still interesting : https://www.hansabiopharma.com/files/Presentations/2021/20211104-HNSA-HCA-event-Gene-Therapy-FINAL.pdfThat thing with AskBio seems really interesting. If they choose to proceed to a full development and commercialization license, Hansa will get a new structure with milestones and royalties. The Sarepta agreement also shows what economic potential such a setup can have. At the same time, we have Généthon in phase 2, and now Renée says they want to further broaden the gene therapy side. A lot is starting to happen there.
- ·2.9.My opinion and not advice 👇
- ·2.9.Surely the gene therapy deal will be reached before December!?Hi StigB! It's absolutely possible. The CEO is now saying that they actively want to expand the gene therapy area through new partnership agreements. With existing collaborations with Sarepta and Genethon, I think the chances are good for December.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 47 | - | - | ||
| 215 | - | - | ||
| 205 | - | - | ||
| 1 570 | - | - | ||
| 1 186 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 468 060 | 468 060 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 468 060 | 468 060 | 0 | 0 |
2026 Q2 -tulosraportti
50 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenScenario where 48.22 is the top after a rise from 23.52. Note! Not a forecast or investment advice. A normal larger pullback could land somewhere around 38–36, while a really strong retracement could take it towards 33. Below 38.78 on a clear close, the picture starts to deteriorate. Then I look towards: 35.88 then 32.96 thereafter 29.18 The 50 %-level at 35.88 is particularly important. If the price falls there and then fails to regain 38–39, it starts to look more like the rise from 23.52 is actually finished." And if 32.96 is also broken with clear price structure, then it is a very deep retracement and the risk increases sharply for a test of 29.18. The negative scenario is: 48.22 top → 42.40 broken → 40.74 broken → 38.78 broken Then I would no longer consider the decline as a normal small pullback. Then 35.88 is my first larger target and thereafter 32.96. Below 32.96, 29.18 becomes interesting. Bullish would be: 48.22 → pullback to 42–43 → higher low → above 48.22 48.22 breakout with volume → 54.0–54.9 → 57.6 → 60.5 → 63.5 My opinion and not advice.Well, how unexpected that you pop up like a jack-in-the-box 😂. How sad to always have such a negative and unrealistic view on everything, almost tragic…
- ·3.9.Regarding gene therapy - Ongoing projects in addition to Renée's information about broadening the gene therapy business Généthon (Crigler-Najjar syndrome): The clinical phase 2 study (GNT-018-IDES) evaluates imlifidase as pre-treatment before gene therapy GNT-0003. The next major milestone is expected in the second half of 2026, when patient recruitment for the study is estimated to be fully completed. This will be followed by data analysis before moving on to registration-enabling studies. Sarepta Therapeutics (Duchenne muscular dystrophy): The initial clinical phase 1 study (where patients with antibodies were successfully pre-treated with imlifidase before receiving gene therapy) has been completed. Strategic discussions are currently underway regarding the next steps and the design of future clinical studies to advance the combination treatment towards the market. (Hansa’s financial participation Potential total deal value for Hansa amounts toup to USD ~400m plus royalties and incremental imlifidase sales - excerpt from presentation see link below ) AskBio (Pompe disease): This collaboration is at an earlier stage where the companies are evaluating the possibility of using imlifidase to enable gene therapy for Pompe disease. The collaboration with AskBio (entered into in 2022) represents a clear broadening of Hansa's indication area within gene therapy. By entering Pompe disease, Hansa showed that their enzyme platform (imlifidase) is not only limited to muscle diseases (like the collaboration with Sarepta in Duchenne muscular dystrophy), but can be applied to entirely new indications. Here below you can read, there is guaranteed more current information, but still interesting : https://www.hansabiopharma.com/files/Presentations/2021/20211104-HNSA-HCA-event-Gene-Therapy-FINAL.pdfThat thing with AskBio seems really interesting. If they choose to proceed to a full development and commercialization license, Hansa will get a new structure with milestones and royalties. The Sarepta agreement also shows what economic potential such a setup can have. At the same time, we have Généthon in phase 2, and now Renée says they want to further broaden the gene therapy side. A lot is starting to happen there.
- ·2.9.My opinion and not advice 👇
- ·2.9.Surely the gene therapy deal will be reached before December!?Hi StigB! It's absolutely possible. The CEO is now saying that they actively want to expand the gene therapy area through new partnership agreements. With existing collaborations with Sarepta and Genethon, I think the chances are good for December.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 47 | - | - | ||
| 215 | - | - | ||
| 205 | - | - | ||
| 1 570 | - | - | ||
| 1 186 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 468 060 | 468 060 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 468 060 | 468 060 | 0 | 0 |